The daily therapy with silodosin can have a role in the treatment of "life-long" premature ejaculation

Introduction. The premature ejaculation is a very common sexual dysfunction especially among the male sexually active population. Recently it has been postulated a role of the silodosin in the treatment of this pathology. Aim of our work is to evaluate the efficacy and the safety of the daily treatment with silodosin in patients affected by premature ejaculation. Materials and methods. Thirty-one patients exclusively affected by “lifelong” premature ejaculation have evaluated the intravaginal ejaculatory latent time and have filled in the premature ejaculation diagnostic tool questionnaire at the baseline and after 30 days of daily “off-label” therapy with silodosin (8 mg). The quality of the sexual life, on the contrary, has been estimated using visual analogic scale before and after pharmacological treatment. Results. It has been observed, after the therapy, a statistically significant lengthening of the medium intravaginal ejaculatory latency time and of the medium score at the premature ejaculation diagnostic tool. All the patients have referred an improvement of the sexual satisfaction after therapy valued through visual analogic scale (p < 0,05). The ejaculatory dysfunctions arisen in 17 patients during the therapy have not turned out to be a problem such as to interfere, in a significant way, on the global sexual well-being. Conclusions. The therapy with silodosin can have a real role in the treatment of the premature ejaculation. We believe further studies are necessary to evaluate the real efficacy and safety of the daily therapy with silodosin (8 mg).